Olpha’s social responsibility projects nominated for prestigious international pharmaceutical award

The social responsibility projects implemented by the Latvian medicines manufacturer Olpha have been recognized and appreciated at the global level. The company has been nominated for the 11th annual Global Generics and Biosimilars Awards in the Corporate Social Responsibility category. The winners will be announced on 9 October in Milan, Italy.

The jury of experts praised Olpha’s social projects such as the scholarship program for young chemistry and biology teachers “Chemistry is among us!”, the provision of fist bumps for newborns in Olaine and other support initiatives aimed at improving the health and well-being of the Latvian population. The support provided by Olpha to the people of Ukraine was also significant. Since the outbreak of the war, Olpha has regularly cooperated with a number of Ukrainian aid organizations, donating both financial resources and useful items. The company’s cooperation with universities was also appreciated, as were its green energy projects and environmental protection activities. 

“Olpha’s goal as a socially responsible company is to contribute to maximizing the quality of people’s lives. While we do this primarily by enabling our patients to regain or improve their health with Olpha medicines, the company takes a much broader view of its contribution to the well-being of society by contributing financially, materially and in various other ways to and supporting socially relevant projects that aim to contribute to a better, happier and healthier community for all of us. We are very pleased that the company’s contribution and efforts have been recognized at such a high international level!” Juris Bundulis, Chairman of the Board of Olpha, is delighted.

In addition to various social projects, the company has been implementing environmentally friendly solutions, which has led to a 28.6% reduction in carbon emissions over the last five years. Olpha has also developed renewable energy sources that contribute to its energy efficiency targets. In autumn 2024, a solar panel park was inaugurated on the company’s premises, which will provide up to 40% of the company’s annual electricity consumption. Work is also underway on a new wastewater system.

It should be noted that Olpha will participate in the global pharmaceutical exhibition “CPHI Milan”, which will take place in Milan, Italy, from 8-10 October. The aim of the exhibition is to bring together pharmaceutical professionals, companies and organizations to promote collaboration, innovation, investment and development.

Participation in the international exhibition is part of the company’s activities aimed at introducing the Olpha brand and its medicines to the people of Western Europe, in order to achieve its goal of becoming one of the top ten European manufacturers of medicines in its therapeutic groups as soon as possible.

About Olpha

Olpha is one of the largest companies in the Baltic States with 50 years of experience in the production of pharmaceuticals and chemical pharmaceutical products. The company's product range is constantly evolving and expanding, currently comprising 60 finished dosage forms, 25 active pharmaceutical ingredients and more than 20 intermediates. The main therapeutic groups include neurology, cardiology, antimicrobial therapy, oncology, urology, as well as drugs for allergies and diabetes. xx products are exported to more than 60 countries. The company employs 840 people. xx has subsidiaries in France, Italy, Spain, Germany and Poland.